Verrica's Big Pitch: Pipeline Promise and YCANTH Success at TD Cowen

WEST CHESTER, PA – February 23, 2026 – Verrica Pharmaceuticals is set to take the stage at the prestigious TD Cowen 46th Annual Health Care Conference next week, an event that has become a critical barometer for the biotech industry. When President and CEO Jayson Rieger presents on March 2nd, he will address an audience of keen-eyed investors and analysts not just with a standard corporate update, but with a narrative of a company at a pivotal inflection point—transitioning from a single-product launch to a diversified dermatology powerhouse.

The presentation in Boston is more than a calendar entry; it's a high-stakes opportunity for Verrica to solidify its growth story, which is built upon the successful commercialization of its flagship product, YCANTH®, and the significant potential of its late-stage pipeline.

Riding the Wave of YCANTH's Success

Verrica's current momentum is undeniably fueled by YCANTH® (cantharidin), the first and only FDA-approved treatment for molluscum contagiosum, a contagious viral skin infection affecting roughly 6 million people in the U.S., mostly children. Before YCANTH®, patients and physicians relied on painful, often scarring, off-label methods or simply waiting for the infection to resolve on its own.

The market has responded with enthusiasm. The company's recent financial reports paint a picture of strong commercial execution. In the third quarter of 2025, Verrica posted revenues of $14.3 million, a figure that blew past analyst estimates. This included a notable $10.7 million in license and collaboration revenue, underscoring the value of its global partnerships. Dispensed YCANTH® units surged approximately 120% year-over-year for the first nine months of 2025, demonstrating accelerating adoption by dermatologists.

This financial performance marked a significant turnaround, with the company reporting a net income of $0.3 million, a stark contrast to the $22.9 million net loss in the same quarter of the previous year. This progress has been bolstered by strategic international partnerships. A key milestone was the approval of YCANTH® in Japan, which triggered a $10 million payment from its partner, Torii Pharmaceutical. Furthermore, positive feedback from the European Medicines Agency (EMA) in late 2025 suggests a path toward a European market filing without the need for additional Phase 3 trials, potentially opening another major market as early as late 2026.

Beyond Molluscum: The Multi-Billion Dollar Wart Market

While the success in treating molluscum provides a solid foundation, what has investors particularly intrigued is Verrica's strategy to expand YCANTH®'s label to treat common warts (verruca vulgaris). This condition represents a vast and largely untapped market, affecting an estimated 22 million individuals in the U.S. alone. Critically, there are currently no FDA-approved prescription therapies for common warts, making it one of the largest unmet needs in medical dermatology.

In December 2025, Verrica dosed the first patient in its global Phase 3 program for this indication, a major step forward. The decision to advance was supported by encouraging Phase 2 data, where 51% of subjects achieved complete clearance of all treatable warts. A successful outcome in the Phase 3 trials could unlock a multi-billion dollar market opportunity and transform YCANTH® into a franchise product.

Significantly, Verrica has structured its development in a financially prudent manner. Its partner, Torii Pharmaceutical, is funding the first $40 million of the global Phase 3 trial costs. This arrangement, covering an estimated 90% of the current budget, substantially de-risks the program for Verrica and allows it to pursue this massive opportunity without placing an undue burden on its balance sheet—a point Mr. Rieger is sure to emphasize to investors.

A New Frontier in Skin Cancer Treatment

Beyond the expanding potential of YCANTH®, Verrica is advancing a second, highly promising asset, VP-315 (ruxotemitide), for the treatment of non-melanoma skin cancers. Licensed from Lytix Biopharma, VP-315 is a first-in-class oncolytic peptide administered directly into tumors, designed to trigger immunogenic cell death and stimulate the body's own immune system to fight the cancer.

The initial focus is on basal cell carcinoma (BCC), the most common form of cancer diagnosed in the United States. Current standard-of-care often involves invasive surgeries that can result in scarring and complications. VP-315 offers the potential for a non-surgical, immunotherapeutic alternative.

Preliminary results from a Phase 2 trial have been compelling. Data released in 2024 showed an 86% overall reduction in tumor size across all treated lesions, with 51% of lesions achieving complete histological clearance. The treatment was also well-tolerated. Following these results, Verrica has aligned with the FDA on an efficient Phase 3 clinical plan, clearing a regulatory path forward. Success in this area would propel Verrica into the lucrative dermatologic oncology market and establish it as a key innovator in skin cancer treatment.

The Investor Perspective: High Stakes at TD Cowen

With a strengthening balance sheet, courtesy of a recent $50 million private placement, and a pipeline brimming with late-stage catalysts, Verrica arrives at the TD Cowen conference from a position of strength. Wall Street has taken notice, with a consensus "Strong Buy" rating from analysts and average 12-month price targets suggesting a potential upside of over 200% from its recent trading price. TD Cowen itself maintains a "Buy" rating with a $20 price target.

However, investors will be listening to Jayson Rieger's presentation for more than just a recap of past achievements. "The market is aware of the potential, but now it's about execution," noted one biotech analyst, speaking on the condition of anonymity. "We need to see a clear, continued trajectory for YCANTH sales, firm timelines for the wart and BCC Phase 3 data readouts, and a confident strategy for managing cash burn through these critical development phases."

The CEO's pitch will need to artfully balance the celebration of current commercial success with a credible vision for future growth. He must convince the audience that the momentum is sustainable and that the company can successfully navigate the clinical and regulatory hurdles for its two major pipeline opportunities. The presentation represents a crucial moment to articulate how these distinct assets—a commercial product for a common pediatric condition, a potential first-in-class therapy for warts, and an innovative treatment for skin cancer—coalesce into a singular, powerful growth story for a leading dermatology therapeutics company.